TA-ASSOCIATES
16.7.2024 19:08:34 CEST | Business Wire | Press release
Francisco Partners (“FP”) and TA Associates (“TA”), leading global investment firms, announced today that they have signed an agreement to become co-controlling shareholders of Orisha, a leading European vertical software company based in France. TA, Orisha’s majority shareholder since 2021, will reinvest in the Company alongside Francisco Partners and Orisha management. The investment will allow Orisha to further advance its growth journey, solidifying its industry leadership through ongoing organic growth, diversification, geographic expansion and strategic acquisitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716551941/en/
Headquartered in Paris, Orisha, formerly known as DL Software, was established in 2003 to bring industry-specific ERP software to a variety of end markets in France. The Group now employs over 1,800 people and offers highly specialized vertical software solutions to over 40,000 customers. Previously supported by 21 Invest France, which is now a minority investor, Orisha has grown revenue by approximately four times and transformed its operating model since TA’s initial investment in 2021, consolidating more than 25 independent business lines into five vertically focused business units: Retail, Health & Safety, Construction, Real Estate and Agri-Food. These business units are now supported by centralized functional teams for finance, HR and technology infrastructure. With over €250 million of revenue expected this year, Orisha’s strategic objective is to offer high-quality and agile software solutions to customers by maintaining customer proximity, accelerating technological innovation and increasing organizational integration.
Jacques Ollivier, CEO of Orisha said, “We are thrilled to onboard Francisco Partners alongside TA as we aim to drive continued growth and further enhance Orisha’s offerings. Both TA and Francisco Partners share our vision for the Company, and we are excited to work together to ensure sustained strong performance in the future. With their support, Orisha is positioned for expansion and to provide our customers with the best solutions.”
“Since our initial investment three years ago, Orisha has experienced meaningful growth and positive transformation under the direction of Jacques and the entire leadership team. We remain deeply confident in the Company’s long-term organic and inorganic growth potential, and we look forward to collaborating with Francisco Partners for the next chapter of Orisha’s journey,” said Maxime Cancre, Director, and Patrick Sader, Managing Director, at TA.
“We are big believers in the power of vertical software and hence fully aligned with Orisha’s mission and vision to build industry-specific solutions. Having tracked the company closely for years, we have been impressed by all that the Orisha team has accomplished, under the leadership of Jacques. Working in partnership with him and TA, we will seek to support Orisha’s next stage of growth by continuing to serve its loyal customer base and expanding thoughtfully into new segments,” said Quentin Lathuille, Principal, and Petri Oksanen, Partner and Co-Head of European Investing, at Francisco Partners.
J.P. Morgan acted as exclusive financial advisor and Latham and Watkins acted as legal advisor to TA. Bryan Garnier acted as financial advisor and Paul Hastings acted as legal advisor to Francisco Partners.
The transaction remains subject to regulatory and antitrust approvals and is expected to close in Q4 2024. Financial terms of the transaction were not disclosed.
About Orisha
Founded in 2003, Orisha is a European software publisher dedicated to companies in the retail, real estate, healthcare, construction and agri-food sectors. Since its creation, Orisha has been helping companies to succeed by offering them solutions tailored to their business needs and essential to their activity (cash collection, commercial and financial management, stock management, CRM, HR, unified commerce…). Each day, Orisha’s solutions facilitate millions of interactions and transactions in a hyper-connected world. Since 2021, Orisha has been backed by TA Associates, a global private equity player and leader in the technology sector. In 2023, Orisha achieved sales in excess of €200m. The group, which was born in France, employs 1,800 people in Europe and supports clients in over 50 countries. More information: https://www.orisha.com
About Francisco Partners
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch 25 years ago, Francisco Partners has invested in more than 450 technology companies, making it one of the most active and longstanding investors in the technology industry. With approximately $45 billion in capital raised, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716551941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom